Tailoring Myelofibrosis Care: Patient Preferences and Challenges
Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration.
EP: 1.Myelofibrosis Care: Pharmacist Role and Treatment Challenges
EP: 2.Blood Shortages Impacting Myelofibrosis Care
EP: 3.Challenges in Myelofibrosis: Red Blood Cell Transfusion Shortages
EP: 4.Impact and Adoption of Momelotinib in Myelofibrosis
EP: 5.Emerging Therapies and Momelotinib Impact
EP: 6.Inpatient to Outpatient: Myelofibrosis Care
EP: 7.Challenges in Outpatient Transition For Myelofibrosis Care
EP: 8.Navigating Myelofibrosis Transitions
EP: 9.Pharmacist-Led Patient Education Strategies
EP: 10.Addressing Socioeconomic Barriers in Myelofibrosis Care
EP: 11.Patient Advocacy in Myelofibrosis Care
EP: 12.Tailoring Myelofibrosis Care: Patient Preferences and Challenges
EP: 13.Advancements in Myelofibrosis Care: Pharmacists' Perspectives
This is a video synopsis/summary of a Peer Exchange involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; Shawn Griffin, PharmD, BCOP; and Robert Mancini, PharmD, BCOP, FHOPA.
In this segment, Mahmoudjafari engages Griffin in a discussion on tailoring treatment plans for myelofibrosis patients based on individual needs and preferences. Griffin emphasizes the pharmacist’s role in symptom management, using tools like the Myeloproliferative Neoplasm Symptom Assessment Form, and highlights the importance of identifying and addressing specific symptoms that matter most to each patient. He underscores the flexibility provided by the array of available therapies, enabling tailored approaches beyond conventional options.
Mahmoudjafari then turns to Mancini to explore challenges in collaborating within the care team. Mancini acknowledges the progress made in integrating pharmacists into oncology care teams but notes challenges related to new roles and managing mail order complexities. He emphasizes the importance of persistently demonstrating value, even if not every recommendation is accepted, and highlights ongoing battles with insurance and mail order issues.
The discussion reveals opportunities for pharmacists in tailoring therapies and navigating challenges in collaborative care for myelofibrosis patients.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
